Osteoclasts—the innate immune cells of the bone
暂无分享,去创建一个
[1] D. Lacey,et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.
[2] Hiroshi Takayanagi,et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.
[3] K. Tan-Takeuchi,et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. , 2003, The Journal of clinical investigation.
[4] J. Woo,et al. Suppression of Osteoprotegerin Expression by Prostaglandin E2 Is Crucially Involved in Lipopolysaccharide-Induced Osteoclast Formation1 , 2004, The Journal of Immunology.
[5] D. G. Walker. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells , 1975, Science.
[6] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[7] W. Dougall,et al. RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.
[8] S. Goldring,et al. Inflammatory Mediators as Essential Elements in Bone Remodeling , 2003, Calcified Tissue International.
[9] Matthew J. Silva,et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts , 2002, Nature Medicine.
[10] M. Takami,et al. A Novel Member of the Leukocyte Receptor Complex Regulates Osteoclast Differentiation , 2002, The Journal of experimental medicine.
[11] A. Keegan,et al. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. , 2003, Blood.
[12] W. Seaman,et al. CMRF-35-Like Molecule-1, a Novel Mouse Myeloid Receptor, Can Inhibit Osteoclast Formation1 , 2003, The Journal of Immunology.
[13] C. Ohlsson,et al. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. , 1998, The Journal of endocrinology.
[14] O. Kollet,et al. The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. , 2007, Annual review of immunology.
[15] R R Miles,et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. , 2001, The Journal of biological chemistry.
[16] Lisa A. Pitcher,et al. T-cell receptor signal transmission: who gives an ITAM? , 2003, Trends in immunology.
[17] S. Teitelbaum,et al. Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.
[18] T. Nakashima,et al. Force‐Induced Osteoclast Apoptosis In Vivo Is Accompanied by Elevation in Transforming Growth Factor β and Osteoprotegerin Expression , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] T. Taniguchi,et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis , 2004, Nature.
[20] I. Reid,et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. , 2002, Human molecular genetics.
[21] H. Takayanagi,et al. Novel osteoclast signaling mechanisms , 2007, Current osteoporosis reports.
[22] S. Latour,et al. Negative regulation of immunoreceptor signaling. , 2002, Annual review of immunology.
[23] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[24] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[25] D. McVicar,et al. Functional association of FcepsilonRIgamma with arginine(632) of paired immunoglobulin-like receptor (PIR)-A3 in murine macrophages. , 1999, Blood.
[26] S. K. Lee,et al. Printed in U.S.A. Copyright © 1999 by The Endocrine Society Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with , 2022 .
[27] L. Lanier,et al. TREM2, a DAP12‐Associated Receptor, Regulates Osteoclast Differentiation and Function , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[28] H. Kitaura,et al. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. , 2003, Bone.
[29] S. Teitelbaum,et al. Successful bone-marrow transplantation for infantile malignant osteopetrosis. , 1980, The New England journal of medicine.
[30] Tak W. Mak,et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis , 2005, The Journal of experimental medicine.
[31] W. Seaman,et al. Pattern Recognition by TREM-2: Binding of Anionic Ligands1 , 2003, The Journal of Immunology.
[32] S. Teitelbaum,et al. M-CSF mediates TNF-induced inflammatory osteolysis. , 2005, The Journal of clinical investigation.
[33] T. Björkman,et al. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. , 2001, Biochemical and biophysical research communications.
[34] Leena Peltonen,et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts , 2000, Nature Genetics.
[35] S Gordon,et al. Macrophage receptors and immune recognition. , 2005, Annual review of immunology.
[36] T. Martin,et al. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. , 1998, Endocrinology.
[37] K. Yudoh,et al. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1β and tumour necrosis factor α , 2004 .
[38] G. Lisignoli,et al. Human osteoclasts express different CXC chemokines depending on cell culture substrate: molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12 , 2003, Histochemistry and Cell Biology.
[39] C. Abram,et al. The Expanding Role for ITAM-Based Signaling Pathways in Immune Cells , 2007, Science's STKE.
[40] L. Hofbauer,et al. Osteoprotegerin deficiency and juvenile Paget's disease. , 2002, The New England journal of medicine.
[41] G. Trinchieri,et al. Fc receptor gamma-chain activation via hOSCAR induces survival and maturation of dendritic cells and modulates Toll-like receptor responses. , 2005, Blood.
[42] R. Baron,et al. The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me(v)/me(v) mutant mice. , 1999, Bone.
[43] L. Lanier,et al. Cutting Edge: Inhibition of TLR and FcR Responses in Macrophages by Triggering Receptor Expressed on Myeloid Cells (TREM)-2 and DAP121 , 2006, The Journal of Immunology.
[44] G D Roodman,et al. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. , 1992, The Journal of clinical investigation.
[45] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[46] L. Hofbauer,et al. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. , 2004, JAMA.
[47] T. Martin,et al. Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation* , 2022 .
[48] D. Lacey,et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.
[49] L. Hood,et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. , 1998, Journal of immunology.
[50] B. Riggs,et al. Regulation of osteoclastogenesis and RANK expression by TGF‐β1 , 2001 .
[51] C. Buonsanti,et al. Impaired Differentiation of Osteoclasts in TREM-2–deficient Individuals , 2003, The Journal of experimental medicine.
[52] M. Colonna,et al. The TREM receptor family and signal integration , 2006, Nature Immunology.
[53] D. McVicar,et al. Functional Association of FcɛRIγ With Arginine632 of Paired Immunoglobulin-Like Receptor (PIR)-A3 in Murine Macrophages , 1999 .
[54] R. Kitazawa,et al. Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone. , 2002, Journal of Biological Chemistry.
[55] L. Lanier,et al. The Signaling Adapter Protein DAP12 Regulates Multinucleation During Osteoclast Development , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[56] S. Mumm,et al. Heritable disorders of the RANKL/OPG/RANK signaling pathway. , 2004, Journal of musculoskeletal & neuronal interactions.
[57] S. Morony,et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.
[58] S. Miller. Rapid activation of the medullary bone osteoclast cell surface by parathyroid hormone , 1978, The Journal of cell biology.
[59] L. Mei,et al. Regulation of osteoclast function and bone mass by RAGE , 2006, The Journal of experimental medicine.
[60] R. Kitazawa,et al. Transforming Growth Factor- (cid:1) Induces Expression of Receptor Activator of NF- (cid:2) B Ligand in Vascular Endothelial Cells Derived from Bone* , 2002 .
[61] Yongwon Choi,et al. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function , 1999, Journal of leukocyte biology.
[62] A. Levine,et al. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. , 2005, Endocrinology.
[63] L. Samelson,et al. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. , 2002, Annual review of immunology.
[64] B. Riggs,et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. , 1998, Biochemical and biophysical research communications.
[65] M. Colonna,et al. Activating and inhibitory functions of DAP12 , 2007, Nature reviews. Immunology.
[66] W. Dougall,et al. A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function* , 2002, The Journal of Biological Chemistry.
[67] S. Yamasaki,et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. , 2000, Biochemical and biophysical research communications.
[68] S. Nishikawa,et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.
[69] L. Lanier,et al. Bone Microenvironment Specific Roles of ITAM Adapter Signaling during Bone Remodeling Induced by Acute Estrogen-Deficiency , 2007, PloS one.
[70] R. Nissenson,et al. PTH Differentially Regulates Expression of RANKL and OPG , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[71] T. Taniguchi,et al. Signaling crosstalk between RANKL and interferons in osteoclast differentiation , 2002, Arthritis research.
[72] O. Salonen,et al. CNS manifestations of Nasu–Hakola disease , 2001, Neurology.
[73] C. Janeway,et al. Innate immune recognition. , 2002, Annual review of immunology.
[74] G. Trinchieri,et al. OSCAR is an FcRγ-associated receptor that is expressed by myeloid cells and is involved in antigen presentation and activation of human dendritic cells , 2004 .
[75] D. Lacey,et al. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .
[76] P. Hudler,et al. Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.
[77] J. Penninger,et al. RANK-L and RANK: T cells, bone loss, and mammalian evolution. , 2002, Annual review of immunology.
[78] W. Zou,et al. Syk, c-Src, the αvβ3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption , 2007, The Journal of Cell Biology.
[79] N. Athanasou,et al. Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. , 1990, Journal of clinical pathology.
[80] L. Lanier,et al. The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. , 2000, Immunology today.
[81] U. Lerner,et al. Inhibition of Hormone and Cytokine-stimulated Osteoclastogenesis and Bone Resorption by Interleukin-4 and Interleukin-13 Is Associated with Increased Osteoprotegerin and Decreased RANKL and RANK in a STAT6-dependent Pathway* , 2006, Journal of Biological Chemistry.
[82] U. Lerner,et al. Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. , 2002, Bone.
[83] Ari Elson,et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells , 2006, Nature Medicine.
[84] R. Wallace,et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.
[85] S. Morony,et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[86] F. Hentati,et al. Nasu-Hakola disease in two Tunisian siblings: new radiological findings , 2000, Neuroradiology.
[87] K. Takagi,et al. Deficiency of SHP-1 protein-tyrosine phosphatase activity results in heightened osteoclast function and decreased bone density. , 1999, The American journal of pathology.
[88] Hiroshi Takayanagi,et al. Mechanistic insight into osteoclast differentiation in osteoimmunology , 2005, Journal of Molecular Medicine.
[89] M. Reth. Antigen receptor tail clue , 1989, Nature.
[90] A. Wetterwald,et al. Role of colony‐stimulating factor‐1 in bone metabolism , 1994, Journal of cellular biochemistry.
[91] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[92] R. Marcus,et al. IGF-I Regulates Osteoprotegerin ( OPG ) and Receptor Activator of Nuclear Factor-B Ligand in Vitro and OPG in Vivo , 2002 .
[93] A. Zallone,et al. c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. , 2003, The Journal of clinical investigation.
[94] K. Yudoh,et al. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. , 2004, Annals of the rheumatic diseases.
[95] U. Lerner,et al. IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-κB Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Mouse Calvariae1 , 2002, The Journal of Immunology.
[96] L. Lanier,et al. Inhibition of Immune Responses by ITAM-Bearing Receptors , 2006, Science's STKE.
[97] S. Akira,et al. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis , 2006, Nature Cell Biology.
[98] L. Lum,et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. , 1999, The Journal of biological chemistry.
[99] J. She,et al. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. , 2006, Biochemical and biophysical research communications.
[100] J. Ravetch,et al. FcR gamma chain deletion results in pleiotrophic effector cell defects. , 1994, Cell.
[101] L. Lum,et al. Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, Journal of Biological Chemistry.
[102] T. Nagy,et al. The Effect of Class A Scavenger Receptor Deficiency in Bone* , 2007, Journal of Biological Chemistry.
[103] c-Fms and the αvβ3 integrin collaborate during osteoclast differentiation , 2003 .
[104] S. Teitelbaum. Osteoclasts: what do they do and how do they do it? , 2007, The American journal of pathology.
[105] S. Akira,et al. MyD88 But Not TRIF Is Essential for Osteoclastogenesis Induced by Lipopolysaccharide, Diacyl Lipopeptide, and IL-1α , 2004, The Journal of experimental medicine.
[106] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[107] A. Villa,et al. Osteopetroses and immunodeficiencies in humans , 2006, Current opinion in allergy and clinical immunology.
[108] L. Peltonen,et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. , 2002, American journal of human genetics.
[109] A. Mócsai,et al. The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase , 2004 .
[110] J. Ravetch,et al. FcR γ chain deletion results in pleiotrophic effector cell defects , 1994, Cell.
[111] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[112] D L Lacey,et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[113] A. Mócsai,et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[114] M. de Vernejoul,et al. Osteoprotegerin and inflammation. , 2002, European cytokine network.
[115] Y. Kadono,et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction , 2006, The Journal of experimental medicine.
[116] Y. Kadono,et al. Segregation of TRAF6‐mediated signaling pathways clarifies its role in osteoclastogenesis , 2001, The EMBO journal.
[117] M. Noda,et al. Involvement of FcRgamma in signal transduction of osteoclast-associated receptor (OSCAR). , 2004, International immunology.
[118] D. Lacey,et al. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. , 1999, Bone.
[119] Jude E. Onyia,et al. Stimulation of Osteoprotegerin (OPG) Gene Expression by Transforming Growth Factor-β (TGF-β) , 2001, The Journal of Biological Chemistry.
[120] L. Lanier,et al. Role of ITAM‐containing adapter proteins and their receptors in the immune system and bone , 2005, Immunological reviews.
[121] S. Reddy,et al. Characterization of immortalized osteoclast precursors developed from mice transgenic for both bcl-X(L) and simian virus 40 large T antigen. , 1999, Endocrinology.
[122] T. Martin,et al. Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction , 2022 .
[123] Y. Toyama,et al. DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells , 2005, The Journal of experimental medicine.
[124] W. Zou,et al. High dose M‐CSF partially rescues the Dap12−/− osteoclast phenotype , 2003, Journal of cellular biochemistry.
[125] L. Peltonen,et al. DAP12/TREM2 Deficiency Results in Impaired Osteoclast Differentiation and Osteoporotic Features , 2003, The Journal of experimental medicine.
[126] T. Kurosaki,et al. Paired Immunoglobulin-like Receptor (PIR)-A Is Involved in Activating Mast Cells through Its Association with Fc Receptor γ Chain , 1998, The Journal of experimental medicine.
[127] L. Piccio,et al. Cutting Edge: TREM-2 Attenuates Macrophage Activation1 , 2006, The Journal of Immunology.
[128] P. Maquet,et al. Nasu-Hakola syndrome: polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia. , 1997, Journal of medical genetics.
[129] T. Watts,et al. TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.
[130] S. Mochizuki,et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.
[131] L. Lanier,et al. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12 , 2005, Nature Immunology.